Preadmission Opioid Use and 1-Year Mortality Following Incident Myocardial Infarction: A Danish Population-Based

Søren Korsgaard1,2, Troels Munch1,2, Erzsébet Horváth-Puhó1,2

  • 1Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark.

Insights

Opioid use before a heart attack significantly increases the risk of death within one year. Current opioid users face the highest mortality risk following myocardial infarction compared to non-users.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Epidemiology

Background:

  • Opioid use is a known risk factor for myocardial infarction and cardiovascular mortality.
  • The prognostic impact of pre-existing opioid use on outcomes after myocardial infarction remains largely uncharacterized.

Purpose of the Study:

  • To investigate the association between pre-admission opioid use and 1-year all-cause mortality in patients experiencing a first myocardial infarction.
  • To identify specific opioid use patterns (current, recent, former) associated with increased mortality risk post-myocardial infarction.

Main Methods:

  • Nationwide population-based cohort study in Denmark (1997-2016) including 162,861 patients hospitalized for incident myocardial infarction.
  • Patients categorized into current (0-30 days), recent (31-365 days), former (>365 days), and non-opioid users based on prescription data.
  • One-year all-cause mortality analyzed using Kaplan-Meier method and Cox regression, adjusting for demographics, comorbidities, and pre-infarction medication use.

Main Results:

  • Current opioid users comprised 8% of the cohort, with a 1-year mortality rate of 42.5%.
  • Compared to non-users (20.5% mortality), current opioid users exhibited a significantly elevated adjusted 1-year all-cause mortality risk (HR 1.26).
  • Neither recent nor former opioid users demonstrated an increased risk of 1-year mortality after adjusting for confounders.

Conclusions:

  • Preadmission opioid use, particularly current use, is independently associated with increased 1-year all-cause mortality following myocardial infarction.
  • Patients with myocardial infarction who are current opioid users represent a high-risk subgroup requiring targeted management strategies.
  • Findings highlight the importance of considering pre-existing opioid use in risk stratification and treatment planning for myocardial infarction patients.

Related Concept Videos

Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
315
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
27
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
363
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
701
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.3K